

Shinichi Kawai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4308992/publications.pdf>

Version: 2024-02-01

69
papers

2,691
citations

257450

24
h-index

182427

51
g-index

70
all docs

70
docs citations

70
times ranked

2840
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 179-186.	2.5	1
2	Efficacy and Safety of Tramadol Hydrochloride Twice-Daily Sustained-Release Bilayer Tablets with an Immediate-Release Component for Chronic Pain Associated with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study. <i>Clinical Drug Investigation</i> , 2022, 42, 403-416.	2.2	5
3	Magnitude of mitral valve closure plays a pivotal role in enhancing the forward blood flow during cardiac massage in dogs with ventricular fibrillation. <i>Journal of Veterinary Medical Science</i> , 2022, , .	0.9	0
4	Alteration in peritoneal cells with the chemokine CX3CL1 reverses age-associated impairment of recognition memory. <i>GeroScience</i> , 2022, 44, 2305-2318.	4.6	2
5	New Assay System Elecsys Anti-p53 to Detect Serum Anti-p53 Antibodies in Esophageal Cancer Patients and Colorectal Cancer Patients: Multi-institutional Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 4007-4015.	1.5	9
6	InÂvivo comparison of dl-sotalol-induced electrocardiographic responses among halothane anesthesia, isoflurane anesthesia with nitrous oxide, and conscious state. <i>Journal of Pharmacological Sciences</i> , 2021, 145, 16-22.	2.5	8
7	Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. <i>Heart and Vessels</i> , 2021, 36, 424-429.	1.2	3
8	Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. <i>Toxicological Sciences</i> , 2021, 181, 125-133.	3.1	2
9	In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa,L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs. <i>Heart and Vessels</i> , 2021, 36, 1088-1097.	1.2	3
10	Plasma pentraxin 3 is associated with progression of radiographic joint damage, but not carotid atherosclerosis, in female rheumatoid arthritis patients: 3-year prospective study. <i>Modern Rheumatology</i> , 2020, 30, 959-966.	1.8	6
11	Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2019, 38, 1571-1578.	2.2	7
12	Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2018, 37, 2169-2178.	2.2	21
13	The efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, YIA-5.	0.0	0
14	The efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-4-26.	0.0	0
15	Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 823-832.	2.5	12
16	Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases. <i>Metabolites</i> , 2016, 6, 28.	2.9	6
17	Efficacy of Vitamin K₂ for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases. <i>Internal Medicine</i> , 2016, 55, 1997-2003.	0.7	8
18	Folypolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 35615.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1078-1090.	2.4	38
20	Apparent Hypothalamic-Pituitary-Adrenal Axis Suppression via Reduction of Interleukin-6 by Glucocorticoid Therapy in Systemic Autoimmune Diseases. <i>PLoS ONE</i> , 2016, 11, e0167854.	2.5	19
21	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , 2015, 42, 799-809.	2.0	39
22	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2014, 24, 8-16.	1.8	28
23	Resistin is associated with the inflammation process in patients with systemic autoimmune diseases undergoing glucocorticoid therapy: comparison with leptin and adiponectin. <i>Modern Rheumatology</i> , 2013, 23, 8-18.	1.8	14
24	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-1052.	1.8	7
25	Resistin is associated with the inflammation process in patients with systemic autoimmune diseases undergoing glucocorticoid therapy: comparison with leptin and adiponectin. <i>Modern Rheumatology</i> , 2013, 23, 8-18.	1.8	9
26	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-52.	1.8	2
27	Serum adipokine profiles in Kawasaki disease. <i>Modern Rheumatology</i> , 2012, 22, 66-72.	1.8	15
28	Tacrolimus down-regulates chemokine expressions on rheumatoid synovial fibroblasts: screening by a DNA microarray. <i>Inflammation Research</i> , 2012, 61, 1385-1394.	4.0	8
29	Serum adipokine profiles in Kawasaki disease. <i>Modern Rheumatology</i> , 2012, 22, 66-72.	1.8	16
30	Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2011, 31, 157-166.	3.7	17
31	Elevated Serum Levels of Resistin, Leptin, and Adiponectin are Associated with C-reactive Protein and also Other Clinical Conditions in Rheumatoid Arthritis. <i>Internal Medicine</i> , 2011, 50, 269-275.	0.7	101
32	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	21
33	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	12
34	DDS of nonsteroidal anti-inflammatory drugs (NSAIDs). <i>Drug Delivery System</i> , 2011, 26, 468-475.	0.0	1
35	Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1679-1685.	2.4	136
36	Aspirin and sodium salicylate inhibit proliferation and induce apoptosis in rheumatoid synovial cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 1675-1679.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Adiponectin stimulates prostaglandin E ₂ production in rheumatoid arthritis synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2010, 62, 1641-1649.	6.7	70
38	Efficacy and Safety of Ketoprofen Patch in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Study. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1171-1179.	2.0	11
39	Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor- α after etanercept administration. <i>International Journal of Rheumatic Diseases</i> , 2010, 13, e67-9.	1.9	30
40	Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. <i>Modern Rheumatology</i> , 2009, 19, 616-621.	1.8	24
41	Pharmacokinetic study and Fc γ 3 receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. <i>Modern Rheumatology</i> , 2009, 19, 329-333.	1.8	18
42	Prostaglandin E2 activates Rap1 via EP2/EP4 receptors and cAMP-signaling in rheumatoid synovial fibroblasts: Involvement of Epac1 and PKA. <i>Prostaglandins and Other Lipid Mediators</i> , 2009, 89, 26-33.	1.9	17
43	Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 218-223.	2.1	67
44	Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2009, 19, 351-357.	1.8	75
45	Pharmacokinetic study and Fc γ 3 receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. <i>Modern Rheumatology</i> , 2009, 19, 329-333.	1.8	10
46	Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2009, 19, 351-357.	1.8	48
47	Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. <i>Modern Rheumatology</i> , 2009, 19, 616-621.	1.8	19
48	Safety profile of tacrolimus in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1393-1397.	2.2	25
49	Pro-apoptotic effect of nonsteroidal anti-inflammatory drugs on synovial fibroblasts. <i>Modern Rheumatology</i> , 2008, 18, 542-551.	1.8	8
50	Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. <i>Modern Rheumatology</i> , 2008, 18, 345-353.	1.8	11
51	Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. <i>Modern Rheumatology</i> , 2008, 18, 345-353.	1.8	8
52	Pro-apoptotic effect of nonsteroidal anti-inflammatory drugs on synovial fibroblasts. <i>Modern Rheumatology</i> , 2008, 18, 542-551.	1.8	5
53	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1162-1167.	0.9	674
54	Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 238-245.	4.3	104

#	ARTICLE	IF	CITATIONS
55	New insights into eicosanoid biosynthetic pathways: implications for arthritis. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 277-291.	3.0	18
56	Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2153-61.	2.0	49
57	A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis. <i>Anticancer Research</i> , 2006, 26, 3229-36.	1.1	5
58	Recent Advances in Nonsteroidal Anti-Inflammatory Drugs. <i>Allergology International</i> , 2005, 54, 209-215.	3.3	26
59	Prostaglandin E synthase in the pathophysiology of arthritis. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 255-261.	1.9	55
60	A Novel Celecoxib Derivative Potently Induces Apoptosis of Human Synovial Fibroblasts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 796-803.	2.5	19
61	Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. <i>Arthritis Research</i> , 2004, 6, R355.	2.0	128
62	Current drug therapy for rheumatoid arthritis. <i>Journal of Orthopaedic Science</i> , 2003, 8, 259-263.	1.1	20
63	Prostaglandin E ₂ is an enhancer of interleukin-1 β -induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2003, 48, 2819-2828.	6.7	79
64	Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Association with Activation of Peroxisome Proliferator-Activated Receptor β in Rheumatoid Synovial Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 18-25.	2.5	72
65	Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. <i>FEBS Letters</i> , 2002, 531, 278-284.	2.8	119
66	Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. <i>Arthritis and Rheumatism</i> , 2002, 46, 3159-3167.	6.7	71
67	Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. <i>Journal of Rheumatology</i> , 2002, 29, 1836-42.	2.0	70
68	Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. <i>European Journal of Pharmacology</i> , 1998, 347, 87-94.	3.5	108
69	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 0, , 1.	1.8	1